IMV-101 Market Summary
Key Factors Driving IMV-101 Growth
1. Significant Unmet Need in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma
Despite advances in anti-CD20 antibodies, BTK inhibitors, bispecific antibodies, and CAR-T therapies, many patients with relapsed/refractory B-NHL eventually progress and require additional treatment options. IMV-101 is being developed specifically for this difficult-to-treat population, where effective therapies can command substantial clinical and commercial value. The ongoing Phase I/IIa study focuses on patients with relapsed/refractory disease, highlighting its potential role in an area of persistent unmet need.
2. Advancement Into Human Clinical Trials
A major value driver for any emerging oncology asset is successful entry into clinical development. IMV-101 entered a Phase I/IIa dose-escalation and dose-expansion study that is actively recruiting patients. The trial is designed to establish safety, determine the recommended Phase II dose (RP2D), and generate preliminary efficacy data. Clinical progression significantly reduces development risk compared with preclinical-stage assets.
3. Opportunity for Expansion Across Multiple B-Cell Malignancies
Although the current trial focuses on B-cell non-Hodgkin lymphoma, successful proof-of-concept could support expansion into additional B-cell malignancies. Many lymphoma-directed therapies eventually expand into related hematologic cancers such as diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, mantle cell lymphoma, and chronic lymphocytic leukemia. This creates a broader long-term commercial opportunity beyond the initial indication. The current trial structure includes both dose-escalation and expansion cohorts, which may facilitate future indication expansion strategies.
4. Early-Mover Potential Within Its Development Category
The current study is designed to identify an optimal dose and generate early efficacy signals. Positive results at this stage could attract strategic partnerships, licensing agreements, or additional financing, which are often important growth catalysts for emerging oncology companies. In oncology, encouraging early clinical data frequently drives substantial increases in program valuation before regulatory approval.
5. Increasing Demand for Targeted Hematologic Cancer Therapies
The treatment landscape in lymphoma continues to shift toward highly targeted therapies that can improve outcomes while reducing systemic toxicity. Investors, pharmaceutical companies, and healthcare systems continue to prioritize innovative therapies for hematologic malignancies because of their strong clinical demand and willingness of payers to reimburse effective treatments in high-risk populations. IMV-101 is positioned within this attractive therapeutic area.
 
6. Potential Strategic Partnership and Licensing Opportunities
Many successful hematology products have achieved commercial success through regional licensing deals, co-development agreements, or acquisition by larger oncology companies. If IMV-101 demonstrates favorable safety and efficacy, it could become an attractive partnering candidate. Such transactions often provide non-dilutive funding and accelerate global development. While no major partnership has been publicly announced, the ongoing clinical program establishes the foundation for future business-development opportunities.
IMV-101 Recent Developments
In December 2025, IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and autoimmune diseases. The company has presented results of the evaluation of its in vitro and in vivo properties.
 
“IMV-101 Sales Forecast, and Market Size Analysis – 2034†report provides comprehensive insights of IMV-101 for potential indication like Diffuse large B cell lymphoma in the 7MM. A detailed picture of IMV-101’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the IMV-101 for potential indications. The IMV-101 market report provides insights about IMV-101’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current IMV-101 performance, future market assessments inclusive of the IMV-101 market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of IMV-101 sales forecasts, along with factors driving its market.
IMV-101 Drug Summary
IMV-101 is an investigational CD19-targeted CAR-T cell therapy being developed by Suzhou Immunofoco Biotechnology Co., Ltd. for the treatment of relapsed or refractory B-cell malignancies and potentially autoimmune diseases. The therapy is engineered to recognize and eliminate CD19-expressing B cells, a key driver of many B-cell lymphomas and certain antibody-mediated autoimmune disorders. By genetically modifying a patient's T cells to express a chimeric antigen receptor (CAR) directed against CD19, IMV-101 aims to induce potent and durable anti-tumor activity through targeted immune-cell killing. Preclinical studies have demonstrated robust in vitro and in vivo antitumor efficacy, supporting its advancement into clinical development. IMV-101 is currently being evaluated in a Phase I/IIa clinical trial in patients with relapsed or refractory B-cell non-Hodgkin lymphoma to assess its safety, tolerability, pharmacokinetics, and preliminary efficacy, with the broader goal of expanding its application to other hematologic malignancies and autoimmune conditions. The report provides IMV-101’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
 
Scope of the IMV-101 Market Report
The report provides insights into:
• A comprehensive product overview including the IMV-101 MoA, description, dosage and administration, research and development activities in potential indication like Diffuse large B cell lymphoma.
• Elaborated details on IMV-101 regulatory milestones and other development activities have been provided in IMV-101 market report.
• The report also highlights IMV-101‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
• The IMV-101 market report also covers the patents information, generic entry and impact on cost cut.
• The IMV-101 market report contains current and forecasted IMV-101 sales for potential indications till 2034.
• Comprehensive coverage of the late-stage emerging therapies for respective indications.
• The IMV-101 market report also features the SWOT analysis with analyst views for IMV-101 in potential indications.
Methodology
The IMV-101 market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
 
IMV-101 Analytical Perspective by DelveInsight
• In-depth IMV-101 Market Assessment
This IMV-101 sales market forecast report provides a detailed market assessment of IMV-101 for potential indication like Diffuse large B cell lymphoma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted IMV-101 sales data uptil 2034.
• IMV-101 Clinical Assessment
The IMV-101 market report provides the clinical trials information of IMV-101 for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
IMV-101 Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
IMV-101 Market Potential & Revenue Forecast
• Projected market size for the IMV-101 and its key indications
• Estimated IMV-101 sales potential (IMV-101 peak sales forecasts)
• IMV-101 Pricing strategies and reimbursement landscape
IMV-101 Competitive Intelligence
• Number of competing drugs in development (pipeline analysis)
• IMV-101 Market positioning compared to existing treatments
• IMV-101 Strengths & weaknesses relative to competitors
IMV-101 Regulatory & Commercial Milestones
• IMV-101 Key regulatory approvals & expected launch timelines
• Commercial partnerships, licensing deals, and M&A activity
IMV-101 Clinical Differentiation
• IMV-101 Efficacy & safety advantages over existing drugs
• IMV-101 Unique selling points
 
IMV-101 Market Report Highlights
• In the coming years, the IMV-101 market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
• The IMV-101 companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence IMV-101’s dominance.
• Other emerging products for Diffuse large B cell lymphoma are expected to give tough market competition to IMV-101 and launch of late-stage emerging therapies in the near future will significantly impact the market.
• A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of IMV-101 in potential indications.
• Analyse IMV-101 cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
• Our in-depth analysis of the forecasted IMV-101 sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of IMV-101 in potential indications.
Key Questions
• What is the class of therapy, route of administration and mechanism of action of IMV-101? How strong is IMV-101’s clinical and commercial performance?
• What is IMV-101’s clinical trial status in each individual indications such as Diffuse large B cell lymphoma and study completion date?
• What are the key collaborations, mergers and acquisitions, licensing and other activities related to the IMV-101 Manufacturers?
• What are the key designations that have been granted to IMV-101 for potential indications? How are they going to impact IMV-101’s penetration in various geographies?
• What is the current and forecasted IMV-101 market scenario for potential indications? What are the key assumptions behind the forecast?
• What are the current and forecasted sales of IMV-101 in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
• What are the other emerging products available and how are these giving competition to IMV-101 for potential indications?
• Which are the late-stage emerging therapies under development for the treatment of potential indications?
• How cost-effective is IMV-101? What is the duration of therapy and what are the geographical variations in cost per patient?
